Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Identifieur interne : 000560 ( France/Analysis ); précédent : 000559; suivant : 000561Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
Auteurs : Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-01.
English descriptors
- KwdEn :
- Adult, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Bromocriptine, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Confidence Intervals, Disease Progression, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine agonist, Double-Blind Method, Double‐blind, controlled study, Drug Therapy, Combination, Early Parkinson's disease, Female, Humans, Indoles (adverse effects), Indoles (therapeutic use), Longitudinal Studies, Male, Middle Aged, Odds Ratio, Parkinson Disease (drug therapy), Regression Analysis, Ropinirole, Selegiline, Selegiline (therapeutic use), Severity of Illness Index, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Bromocriptine, Dopamine Agonists, Indoles.
- chemical , therapeutic use : Antiparkinson Agents, Bromocriptine, Dopamine Agonists, Indoles, Selegiline.
- drug therapy : Parkinson Disease.
- Adult, Aged, Confidence Intervals, Disease Progression, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Longitudinal Studies, Male, Middle Aged, Odds Ratio, Regression Analysis, Severity of Illness Index, Treatment Outcome.
Abstract
We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.
Url:
DOI: 10.1002/mds.870130112
Affiliations:
- Autriche, France, Israël, Italie, Pays-Bas, Royaume-Uni
- Angleterre, Grand Londres, Groningue (province), Latium, Midi-Pyrénées
- Groningue, Londres, Rome, Toulouse
- Université Toulouse III - Paul Sabatier, Université de Toulouse
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001257
- to stream Istex, to step Curation: 001257
- to stream Istex, to step Checkpoint: 003639
- to stream PubMed, to step Corpus: 004518
- to stream PubMed, to step Curation: 004518
- to stream PubMed, to step Checkpoint: 004338
- to stream Ncbi, to step Merge: 004E67
- to stream Ncbi, to step Curation: 004E67
- to stream Ncbi, to step Checkpoint: 004E67
- to stream Main, to step Merge: 007E16
- to stream Main, to step Curation: 004F04
- to stream Main, to step Exploration: 004F04
- to stream France, to step Extraction: 000560
Links to Exploration step
ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation><country>France</country><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130112</idno><idno type="url">https://api.istex.fr/document/9B528618A0950D500A47E6F3C3B5917D43BDAB73/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001257</idno><idno type="wicri:Area/Istex/Curation">001257</idno><idno type="wicri:Area/Istex/Checkpoint">003639</idno><idno type="wicri:doubleKey">0885-3185:1998:Korczyn:ropinirole:versus:bromocriptine</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9452325</idno><idno type="wicri:Area/PubMed/Corpus">004518</idno><idno type="wicri:Area/PubMed/Curation">004518</idno><idno type="wicri:Area/PubMed/Checkpoint">004338</idno><idno type="wicri:Area/Ncbi/Merge">004E67</idno><idno type="wicri:Area/Ncbi/Curation">004E67</idno><idno type="wicri:Area/Ncbi/Checkpoint">004E67</idno><idno type="wicri:doubleKey">0885-3185:1998:Korczyn A:ropinirole:versus:bromocriptine</idno><idno type="wicri:Area/Main/Merge">007E16</idno><idno type="wicri:Area/Main/Curation">004F04</idno><idno type="wicri:Area/Main/Exploration">004F04</idno><idno type="wicri:Area/France/Extraction">000560</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study</title><author><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name><affiliation wicri:level="1"><country xml:lang="fr">Israël</country><wicri:regionArea>Department of Neurology, Sackler Faculty of Medicine, Tel‐Aviv University, Tel‐Aviv</wicri:regionArea><wicri:noRegion>Tel‐Aviv</wicri:noRegion></affiliation></author><author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Neurology Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Neurology, University Hospital, Groningen</wicri:regionArea><placeName><settlement type="city">Groningue</settlement><region nuts="2" type="province">Groningue (province)</region></placeName></affiliation></author><author><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name><affiliation wicri:level="1"><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion></affiliation></author><author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Department of Clinical Pharmacology, Clinical Investigation Center, INSERM U455, University Hospital, Toulouse</wicri:regionArea><placeName><settlement type="city">Toulouse</settlement></placeName><placeName><settlement type="city">Toulouse</settlement><region type="region" nuts="2">Midi-Pyrénées</region></placeName><orgName type="university" n="3">Université Toulouse III - Paul Sabatier</orgName><orgName type="institution" wicri:auto="newGroup">Université de Toulouse</orgName></affiliation></author><author><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name><affiliation wicri:level="3"><country xml:lang="fr">Italie</country><wicri:regionArea>Department of Neurological Science, University la Sapienza, Rome</wicri:regionArea><placeName><settlement type="city">Rome</settlement><region nuts="2">Latium</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-01">1998-01</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="46">46</biblScope><biblScope unit="page" to="51">51</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9B528618A0950D500A47E6F3C3B5917D43BDAB73</idno><idno type="DOI">10.1002/mds.870130112</idno><idno type="ArticleID">MDS870130112</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Bromocriptine</term><term>Bromocriptine (adverse effects)</term><term>Bromocriptine (therapeutic use)</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Dopamine agonist</term><term>Double-Blind Method</term><term>Double‐blind, controlled study</term><term>Drug Therapy, Combination</term><term>Early Parkinson's disease</term><term>Female</term><term>Humans</term><term>Indoles (adverse effects)</term><term>Indoles (therapeutic use)</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Parkinson Disease (drug therapy)</term><term>Regression Analysis</term><term>Ropinirole</term><term>Selegiline</term><term>Selegiline (therapeutic use)</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Indoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Bromocriptine</term><term>Dopamine Agonists</term><term>Indoles</term><term>Selegiline</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Confidence Intervals</term><term>Disease Progression</term><term>Double-Blind Method</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Longitudinal Studies</term><term>Male</term><term>Middle Aged</term><term>Odds Ratio</term><term>Regression Analysis</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the efficacy and safety of ropinirole with that of bromocriptine after 6 months of treatment in a planned interim analysis of a 3‐year, double‐blind, randomized, multicenter study of 335 patients with early Parkinson's disease requiring dopaminergic therapy. Patients, treated with or without selegiline, received either ropinirole or bromocriptine. The mean Unified Parkinson's Disease Rating Scale (UPDRS) total motor examination scores (Part III) at baseline were similar in the four strata. Overall, and in the non‐selegiline subgroup, the percentage improvement in the UPDRS total motor examination score was significantly higher for ropinirole than for bromocriptine, as was the proportion of “responders.” In the selegiline subgroup, however, there was no significant difference between treatments. Similarly, in the non‐selegiline subgroup, there was a significantly higher proportion of “improvers” on the Clinical Global Impression scale with ropinirole than with bromocriptine, whereas in the selegiline subgroup, there was no significant difference. Emergent adverse events occurred in 80% of patients in both treatment groups, the principal symptom in each group being nausea. The incidence of serious adverse events was low (3% for ropinirole, 6.6% for bromocriptine). The data indicate that (a) in the absence of selegiline, ropinirole is effective and superior to bromocriptine; and (b) selegiline does not affect the response in patients treated with ropinirole, but enhances the effects of bromocriptine.</div></front></TEI><affiliations><list><country><li>Autriche</li><li>France</li><li>Israël</li><li>Italie</li><li>Pays-Bas</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Groningue (province)</li><li>Latium</li><li>Midi-Pyrénées</li></region><settlement><li>Groningue</li><li>Londres</li><li>Rome</li><li>Toulouse</li></settlement><orgName><li>Université Toulouse III - Paul Sabatier</li><li>Université de Toulouse</li></orgName></list><tree><country name="Israël"><noRegion><name sortKey="Korczyn" sort="Korczyn" uniqKey="Korczyn" last="Korczyn">Korczyn</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name></region></country><country name="Pays-Bas"><region name="Groningue (province)"><name sortKey="Brunt, Ehrout R" sort="Brunt, Ehrout R" uniqKey="Brunt E" first="Ehrout R." last="Brunt">Ehrout R. Brunt</name></region></country><country name="Autriche"><noRegion><name sortKey="Poewe, Warner H" sort="Poewe, Warner H" uniqKey="Poewe W" first="Warner H." last="Poewe">Warner H. Poewe</name></noRegion></country><country name="France"><noRegion><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name></noRegion></country><country name="Italie"><region name="Latium"><name sortKey="Stocchi, Fabrizzio" sort="Stocchi, Fabrizzio" uniqKey="Stocchi F" first="Fabrizzio" last="Stocchi">Fabrizzio Stocchi</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000560 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000560 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:9B528618A0950D500A47E6F3C3B5917D43BDAB73
|texte= Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study
}}
| This area was generated with Dilib version V0.6.23. |  |